Swedish University Hospital improves monitoring of treatment efficacy in multiple sclerosis with Synthetic MRI innovation
The LEAD-company SyntheticMR AB, a subsidiary to Accelerator
Nordic AB, has secured an order for their magnetic resonance
imaging software from Umeå University Hospital through their
partner Sectra. The software will be used in clinical practice to
monitor the treatment efficacy of multiple sclerosis (MS).
The software, SyMRI Diagnostics, includes tools to
automatically estimate a measure for brain atrophy and, with minor
manual interaction, retrieve the volume of local brain structures
and lesions. "SyMRI enables us to retrieve accurate values on the
patients status that we could not get before", says Dr Richard
Birgander, Neuroradiologist at Umeå University Hospital. "We have
analyzed the softwares functionality and the results look very
good, which has led to a decision to introduce it in regular
"Magnetic resonance imaging (MRI) generally has been about looking
at pictures and trying to interpret them. SyMRI finally provides us
with objective numbers", says Dr Anders Svenningsson, Neurologist
at Umeå University Hosptial. "My goal is to integrate the SyMRI
approach into the Swedish MS register to have more accurate
follow-up possibilities for these patients". The Swedish MS
register is a nation-wide database that strives to improve care and
convey knowledge of Multiple Sclerosis.
The software will be seamlessly integrated in the
hospital's radiology IT solutions from Sectra. "Offering
third-party clinical innovations like SyMRI Diagnostics tightly
integrated in our own IT solutions is an important part of our
mission to offer our customers ways to improve their efficiency and
the quality of care for their patients," says Dr Torbjörn
Kronander, President of Sectras medical operations.
SyntheticMR has a long standing relationship with Umeå University
Hospital, where the SyMRI Diagnostics product has been evaluated on
site since 2009 in order to better understand how the software can
be used in clinical practice.
For additional information please contact:
Andreas Bunge, CEO Accelerator Nordic AB, +46 708 24 25 25.